5. Amgen and Cytokinetics

Who: Amgen
With: Cytokinetics
What: $675 million alliance

Summary: Cytokinetics optioned its experimental heart failure drug to Amgen in exchange for a $75 million payment and more than $600 million in development and sales milestones. CK-1827452, which is about to enter Phase II, triggers a protein that causes the heart to contract as it pumps blood. About five million Americans suffer from cardiovascular disease characterized by insufficient blood flow. As part of the deal, Amgen agreed to pay another $50 million if it decides to exercise the option and take over development of the therapy. Cytokinetics made off with $42 million in cash and sold $33 million of its shares to Amgen at a hefty 27 percent premium. Release

Related Article:
Cytokinetics, Amgen ink heart drug deal. Report

5. Amgen and Cytokinetics

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.